Page last updated: 2024-11-05

decalin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Decalin is a bicyclic saturated hydrocarbon with the formula C10H18. It is a colorless, odorless liquid that is insoluble in water but soluble in organic solvents. Decalin is a synthetic compound that is not found naturally. It is produced by the catalytic hydrogenation of naphthalene. Decalin is used as a solvent and a plasticizer. It is also used as a starting material for the synthesis of other chemicals. Decalin is a relatively unreactive compound but can be oxidized to decalone and decalol. Decalin is studied for its potential applications in the synthesis of new materials and pharmaceuticals. It is also used as a model compound for the study of the properties of saturated hydrocarbons.'

decalin: RN given refers to cpd without isomeric designation; don't confuse with decaline which has a nitrogen at the juncture of the two rings; [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

trans-decalin : The trans-stereoisomer of decalin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

decalin : An ortho-fused bicyclic hydrocarbon that is the decahydro- derivative of naphthalene. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7044
CHEMBL ID1491920
CHEBI ID38860
CHEBI ID38853
CHEBI ID38863
MeSH IDM0050289

Synonyms (123)

Synonym
AKOS009031622
naphthalene, decahydro-, cis-
naphthalene, decahydro-, trans-
nsc-77453
trans-decalin
cis-decalin
naphthalene, cis-
nsc77453
nsc-77452
cis-bicyclo[4.4.0]decane
trans-perhydronaphthalene
trans-decahydronaphthalene ,
nsc77452
493-02-7
cis-decahydronaphthalene
decahydronaphthalene, trans-
trans-bicyclo[4.4.0]decane
cis-perhydronaphthalene
decahydronaphthalene
naphthalene, decahydro-
inchi=1/c10h18/c1-2-6-10-8-4-3-7-9(10)5-1/h9-10h,1-8h
493-01-6
bicyclo[4.4.0]decane
naphthan
nsc-406139
naphthane
wln: l66tj
91-17-8
dekalina
nsc406139
de-kalin
dekalin
naphthalane
perhydronaphthalene
NCGC00090716-01
brn 0878165
bicyclo(4.4.0)decane
dekalina [polish]
hsdb 287
einecs 202-046-9
un1147
nsc 406139
ccris 3410
ai3-01256
decalin
cis-decahydronaphthalene, 99%
trans-decahydronaphthalene, 99%
t-decalin
decahydronaphthalin
CHEBI:38860
dekahydronaphthalin
c-decahydronaphthalene
CHEBI:38853 ,
c-decalin
CHEBI:38863
(4ar,8ar)-decahydronaphthalene
(4as,8as)-decahydronaphthalene
MLS001055339
smr000673566
D0007
D0009
D0008
1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalene
D1738
A843747
NCGC00090716-02
HMS3039O03
tox21_200222
dtxcid304912
dtxsid1024912 ,
NCGC00257776-01
cas-91-17-8
AKOS016010284
STL280340
unii-88451q4xyf
3-05-00-00245 (beilstein handbook reference)
ec 202-046-9
88451q4xyf ,
decahydronaphthalene [un1147] [flammable liquid]
einecs 207-771-4
nsc 77452
trans-bicyclo(4.4.0)decane
cis-bicyclo(4.4.0)decane
nsc 77453
einecs 207-770-9
FT-0623939
FT-0623872
FT-0632224
decalin [mi]
decahydronaphthalene [hsdb]
decahydronaphthalene [who-dd]
CHEMBL1491920
AKOS025295369
decahydronaphtalene
trans decalin
(e)-decahydronaphthalene
decahydronaphthalene, (e)-
(z)-decahydronaphthalene
decahydronaphthalene, (z)-
decahydronaphthalene, cis
decanhydronaphthalene
un 1147
STR05788
W-109334
mfcd00004130
decahydronaphthalene, cis + trans
mfcd00064189
mfcd00064191
cis-decahydronaphthalene, purum, >=98.0% (gc)
naphthalene, decahydro-, trans-; trans-decahydronaphthalene; t-decalin; trans-bicyclo[4.4.0]decane; trans-decalin; trans-perhydronaphthalene
DTXSID00873337
Q415454
Q27118002
Q27118000
decalin(r)
DTXSID90883405
BS-23873
BS-23504
AT32906
AT32907
naphthalene-1,2,3,4,5,6,7,8-d8, decahydro-d10-
SY128056
Z104474658

Research Excerpts

Overview

Decalin is an organic glass former. A cis/trans mixture exhibits the highest known degree of fragility in a molecular system.

ExcerptReferenceRelevance
"Decalin is a heavy liquid where the risk of displacement is high."( Repeated subretinal surgery and removal of subretinal decalin is well tolerated - evidence from a porcine model.
Heegaard, S; Kiilgaard, JF; Kjær, TW; Klemp, K; la Cour, M; Sørensen, NB, 2017
)
1.42
"Decalin is an organic glass former, for which a cis/trans mixture exhibits the highest known degree of fragility in a molecular system."( Anharmonicity in a fragile glass-former probed by inelastic neutron scattering.
Plazanet, M; Schober, H, 2008
)
1.07

Effects

ExcerptReferenceRelevance
"Wakodecaline C has unique structural features containing a tetrahydrofuran-fused decalin skeleton and tetramic acid moiety, which are connected through a double bond."( Wakodecaline C, new tetrahydrofuran-fused decalin metabolite isolated from fungus Pyrenochaetopsis sp. RK10-F058.
Futamura, Y; Kato, N; Koshino, H; Nogawa, T; Okano, A; Osada, H; Shimizu, T; Takahashi, S, 2023
)
1.95

Toxicity

ExcerptReferenceRelevance
"A subchronic 90-day inhalation study was conducted to determine the toxic effects of decalin, a commonly used industrial solvent."( A 90-day vapor inhalation toxicity study of decalin.
Amster, RL; Bruner, RH; Cowan, MJ; Gaworski, CL; Haun, CC; MacEwen, JD; Vernot, EH, 1985
)
0.75

Bioavailability

ExcerptReferenceRelevance
" This unique phase transformation phenomenon can be a simple and effective method to improve the aqueous solubility and bioavailability of poorly soluble drug molecules."( Spontaneous crystalline-to-amorphous phase transformation of organic or medicinal compounds in the presence of porous media, part 1: thermodynamics of spontaneous amorphization.
Bogner, RH; Qian, KK, 2011
)
0.37

Dosage Studied

Kidneys from male and female Wistar rats dosed with 1 of 3 chemically unrelated pharmacological agents were examined by light and electron microscopy. Extracts of kidney homogenates from male rats, but not from females, dosing with cis- and trans-decalin yielded cis-2-decalone and trans+decalone, respectively.

ExcerptRelevanceReference
" This histological change was accompanied by a treatment-related increase in alpha 2u-globulin in males only and a greater accumulation of radioactivity in renal cortex of the male rat compared with that in the females dosed with [14C]d-limonene."( Acute and subchronic nephrotoxicity of d-limonene in Fischer 344 rats.
Alden, CL; Ridder, GM; Webb, DR, 1989
)
0.28
"Kidneys from male and female Wistar rats dosed with 1 of 3 chemically unrelated pharmacological agents, a pyrazoline BW540C, a naphthoquinone BW58C and the levoisomer of tetramisole, levamisole or the light hydrocarbon Decalin, were examined by light and electron microscopy."( Induction and exacerbation of hyaline droplet formation in the proximal tubular cells of the kidneys from male rats receiving a variety of pharmacological agents.
Astbury, PJ; Morgan, RJ; Parsons, DN; Port, CJ; Read, NG, 1988
)
0.46
" Extracts of kidney homogenates from male rats, but not from females, dosed with cis- and trans-decalin yielded cis-2-decalone and trans-2-decalone, respectively."( Metabolism of nephrotoxic cis- and trans-decalin in Fischer-344 rats.
Olson, CT; Serve, MP; Yu, KO, 1986
)
0.76
"Male and female Fischer 344 rats were given decalin by oral gavage for 5 or 12 consecutive days in order to determine whether oral dosing would result in light microscopically evident renal effects that were comparable to those that have been observed after inhalation exposure."( Decalin-induced nephrotoxicity: light and electron microscopic examination of the effects of oral dosing on the development of kidney lesions in the rat.
Alden, CL; Burns, JL; Kanerva, RL; Stone, LC, 1987
)
1.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
solventA liquid that can dissolve other substances (solutes) without any change in their chemical composition.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
ortho-fused bicyclic hydrocarbon
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency16.35350.004110.890331.5287AID504467
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.38720.011212.4002100.0000AID1030
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency63.92950.000214.376460.0339AID720692
Histone H2A.xCricetulus griseus (Chinese hamster)Potency131.44300.039147.5451146.8240AID1224845
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency17.84400.000627.21521,122.0200AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency10.00000.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency0.10320.004611.374133.4983AID624297
Nuclear receptor ROR-gammaHomo sapiens (human)Potency66.82420.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (202)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (11.39)18.7374
1990's9 (4.46)18.2507
2000's72 (35.64)29.6817
2010's77 (38.12)24.3611
2020's21 (10.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.20 (24.57)
Research Supply Index5.38 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index111.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (66.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.93%)5.53%
Reviews7 (3.27%)6.00%
Case Studies1 (0.47%)4.05%
Observational0 (0.00%)0.25%
Other204 (95.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]